Ofri Mosenzon - Publications, H-index & Citations

Ofri Mosenzon

Hadassah Medical Center

55H指数

264论文数

2.8W被引数

收录论文 117

发表时间

Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data 2型糖尿病患者中胰高血糖素样肽-1受体激动剂与其他降糖药对肾脏结局的影响：基于真实世界数据的系统评价与Meta分析

diabetes metabolism research and reviews

IF0

2025-07-23

OAAI

Alisa Fishkin; Aliza Rozenberg; Meir Schechter; Dvora R. Sehtman-Shachar; Genya Aharon-Hananel; Gil Leibowitz; Ilan Yanuv; Ofri Mosenzon

Normoalbuminuria-is it normal? The association of urinary albumin within the 'normoalbuminuric' range with adverse cardiovascular and mortality outcomes: A systematic review and meta-analysis

DIABETES OBESITY & METABOLISM

IF5.7

2024-07-17

OAAI

Sehtman-Shachar, Dvora R.; Yanuv, Ilan; Schechter, Meir; Fishkin, Alisa; Aharon-Hananel, Genya; Leibowitz, Gil; Rozenberg, Aliza; Mosenzon, Ofri

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

DIABETES CARE

IF16.6

2023-08-09

OAAI

Moura, Filipe A.; Berg, David D.; Bellavia, Andrea; Dwyer, Jamie P.; Mosenzon, Ofri; Scirica, Benjamin M.; Wiviott, Stephen D.; Bhatt, Deepak L.; Raz, Itamar; Feinberg, Mark W.; Braunwald, Eugene; Morrow, David A.; Sabatine, Marc S.

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2023-07-27

OAAI

Rosenstock, Julio; Bain, Stephen C.; Gowda, Amoolya; Jodar, Esteban; Liang, Bo; Lingvay, Ildiko; Nishida, Tomoyuki; Trevisan, Roberto; Mosenzon, Ofri

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study

DIABETES OBESITY & METABOLISM

IF5.7

2023-07-04

OAAI

Rossing, Peter; Anker, Stefan D. D.; Filippatos, Gerasimos; Pitt, Bertram; Ruilope, Luis M. M.; Billings, Liana K. K.; Green, Jennifer B. B.; Koya, Daisuke; Mosenzon, Ofri; Pantalone, Kevin M. M.; Ahlers, Christiane; Lage, Andrea; Lawatscheck, Robert; Scalise, Andrea; Bakris, George L. L.

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2023-06-29

OAAI

Cohen, Cheli Melzer; Schechter, Meir; Rozenberg, Aliza; Yanuv, Ilan; Sehtman-Shachar, Dvora R.; Fishkin, Alisa; Rosenzweig, Doron; Chodick, Gabriel; Karasik, Avraham; Mosenzon, Ofri

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

DIABETES OBESITY & METABOLISM

IF5.7

2023-06-29

OAAI

Schechter, Meir; Cohen, Cheli Melzer; Zelter, Tamir; Yanuv, Ilan; Rozenberg, Aliza; Chodick, Gabriel; Karasik, Avraham; Mosenzon, Ofri

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

CARDIOVASCULAR DIABETOLOGY

IF10.6

2023-05-27

OAAI

Schechter, Meir; Cohen, Cheli Melzer; Fishkin, Alisa; Rozenberg, Aliza; Yanuv, Ilan; Sehtman-Shachar, Dvora R.; Chodick, Gabriel; Clark, Alice; Abrahamsen, Trine J.; Lawson, Jack; Karasik, Avraham; Mosenzon, Ofri

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

JAMA CARDIOLOGY

IF14.1

2023-05-01

OAAI

Zelniker, Thomas A.; Wiviott, Stephen D.; Mosenzon, Ofri; Goodrich, Erica L.; Jarolim, Petr; Cahn, Avivit; Bhatt, Deepak L.; Leiter, Lawrence A.; McGuire, Darren K.; Wilding, John; Averkov, Oleg; Budaj, Andrzej; Parkhomenko, Alexander; Ray, Kausik K.; Gause-Nilsson, Ingrid; Langkilde, Anna Maria; Fredriksson, Martin; Raz, Itamar; Sabatine, Marc S.; Morrow, David A.

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

JCI INSIGHT

IF6.1

2023-04-10

OAAI

Kogot-Levin, Aviram; Riahi, Yael; Abramovich, Ifat; Mosenzon, Ofri; Agranovich, Bella; Kadosh, Liat; Schyr, Rachel Ben-Haroush; Kleiman, Doron; Hinden, Liad; Cerasi, Erol; Ben-Zvi, Danny; Bernal-Mizrachi, Ernesto; Tam, Joseph; Gottlieb, Eyal; Leibowitz, Gil

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

KIDNEY INTERNATIONAL

IF12.6

2023-04-01

OAAI

Tuttle, Katherine R.; Bosch-Traberg, Heidrun; Cherney, David Z. I.; Hadjadj, Samy; Lawson, Jack; Mosenzon, Ofri; Rasmussen, Soren; Bain, Stephen C.

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

CARDIOVASCULAR DIABETOLOGY

IF10.6

2023-03-24

OAAI

Lingvay, Ildiko; Mosenzon, Ofri; Brown, Katelyn; Cui, Xuewei; O'Neill, Ciara; Lando, Laura Fernandez; Patel, Hiren

Diabetes and Stroke: What Are the Connections?糖尿病和中风: 有什么联系？

stroke

IF8.6

2023-01-31

OAAI

Mosenzon, Ofri; Cheng, Alice Y. Y.; Rabinstein, Alejandro A.; Sacco, Simona

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD

ANNALS OF INTERNAL MEDICINE

IF15.2

2023-01-01

OAAI

Schechter, Meir; Jongs, Niels; Chertow, Glenn M.; Mosenzon, Ofri; McMurray, John J., V; Correa-Rotter, Ricardo; Rossing, Peter; Langkilde, Anna Maria; Sjostrom, C. David; Toto, Robert D.; Wheeler, David C.; Heerspink, Hiddo J. L.

Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study

CLINICAL KIDNEY JOURNAL

IF4.6

2022-12-23

OAAI

Kliuk-Ben Bassat, Orit; Schechter, Meir; Ashtamker, Natalia; Yanuv, Ilan; Rozenberg, Aliza; Hirshberg, Boaz; Grupper, Ayelet; Vaisman, Nachum; Brill, Silviu; Mosenzon, Ofri

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

DIABETES CARE

IF16.6

2022-11-18

OAAI

Pollack, Rena; Raz, Itamar; Wiviott, Stephen D.; Goodrich, Erica L.; Murphy, Sabina A.; Yanuv, Ilan; Rozenberg, Aliza; Mosenzon, Ofri; Langkilde, Anna Maria; Gause-Nilsson, Ingrid A. M.; Bhatt, Deepak L.; Leiter, Lawrence A.; McGuire, Darren K.; Wilding, John P. H.; Sabatine, Marc S.; Cahn, Avivit

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

KIDNEY INTERNATIONAL REPORTS

IF5.7

2022-11-01

OAAI

Cherney, David Z. I.; Hadjadj, Samy; Lawson, Jack; Mosenzon, Ofri; Tuttle, Katherine; Vrhnjak, Blaz; Rasmussen, Soren; Bain, Stephen C.

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

DIABETES OBESITY & METABOLISM

IF5.7

2022-10-24

OAAI

Ostergaard, Helena Bleken; Humphreys, Valerie; Hengeveld, Ellen Margo; Honore, Julie Broe; Mach, Francois; Visseren, Frank L. J.; Westerink, Jan; Yadav, Gourav; Mosenzon, Ofri

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

CARDIOVASCULAR DIABETOLOGY

IF10.6

2022-09-02

OAAI

Mosenzon, Ofri; Capehorn, Matthew S.; De Remigis, Alessandra; Rasmussen, Soren; Weimers, Petra; Rosenstock, Julio

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial

JAMA CARDIOLOGY

IF14.1

2022-09-01

OAAI

Oyama, Kazuma; Raz, Itamar; Cahn, Avivit; Goodrich, Erica L.; Bhatt, Deepak L.; Leiter, Lawrence A.; McGuire, Darren K.; Wilding, John P. H.; Gause-Nilsson, Ingrid A. M.; Mosenzon, Ofri; Sabatine, Marc S.; Wiviott, Stephen D.

研究方向